DK2953977T3 - Immunimagografimiddel til anvendelse ved antistof-lægemiddel-konjugatterapi - Google Patents
Immunimagografimiddel til anvendelse ved antistof-lægemiddel-konjugatterapi Download PDFInfo
- Publication number
- DK2953977T3 DK2953977T3 DK14717073.2T DK14717073T DK2953977T3 DK 2953977 T3 DK2953977 T3 DK 2953977T3 DK 14717073 T DK14717073 T DK 14717073T DK 2953977 T3 DK2953977 T3 DK 2953977T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- binding protein
- immunoglobulin
- ser
- gly
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Optics & Photonics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
Claims (15)
1. Antistoflignende bindingsprotein, der specifikt binder den tumorassocierede MUCl-syaloglycotop CA6, der er kendetegnet ved, at det antistoflignende bindingsprotein omfatter to polypeptider med strukturer som vist ved formlerne [I] og [II] nedenfor: Vli-Li-VL2-Cl [I] Vh1-Ij2-Vh2-Ch1 [II] hvor: Vli er et variabelt domæne af let kæde af immunoglobulin, der er afledt fra DS6-antistoffet; Vl2 er et variabelt domæne af let kæde af immunoglobulin, der er afledt fra DS6-antistoffet; Vhi er et variabelt domæne af tung kæde af immunoglobulin, der er afledt fra DS6-antistoffet; Vh2 er et variabelt domæne af tung kæde af immunoglobulin, der er afledt fra DS6-antistoffet; Cl er et konstant domæne af let kæde af immunoglobulin, såsom et humant IGKC konstant domæne af let kæde af immunoglobulin; Chi er et immunoglobulin Chi konstant domæne af tung kæde, såsom et humant immunoglobulin Chi konstant domæne af tung kæde af; Li og L2 er aminosyrelinkere; og hvor polypeptiderne med formel [I] og polypeptiderne med formel [II] danner et bivalent monospecifikt tandem- immunoglobulin-antistoflignende bindingsprotein, hvor polypeptidet med formel [I] omfatter en sekvens, der er mindst 80 % identisk med SEQ ID NO: 1, og polypeptidet med formel [II] omfatter en sekvens, der er mindst 80 % identisk med SEQ ID NO: 7.
2. Antistoflignende bindingsprotein ifølge krav 1, hvor Vli og Vl2 er defineret ved sekvensen SEQ ID NO: 2; og VHi og VH2 er defineret ved sekvensen SEQ ID NO: 8.
3. Antistoflignende bindingsprotein ifølge krav 1 eller krav 2, hvor Li er GGGGS eller GGGGSGGGGS (SEQ ID NO: 3).
4. Antistoflignende bindingsprotein ifølge et hvilket som helst af kravene 1 til 3, hvor L2 er GGGGS eller GGGGSGGGGS (SEQ ID NO: 3).
5. Antistoflignende bindingsprotein ifølge et hvilket som helst af kravene 1 til 4, hvor polypeptidet med formel [I] omfatter aminosyresekvensen SEQ ID NO: 1.
6. Antistoflignende bindingsprotein ifølge et hvilket som helst af kravene 1 til 5, hvor polypeptidet med formel [II] omfatter aminosyresekvensen SEQ ID NO: 7.
7. Antistoflignende bindingsprotein ifølge et hvilket som helst af kravene 1 til 6, der yderligere omfatter mindst ét radioaktivt mærke, imagografimiddel, terapeutisk middel eller diagnostisk middel.
8. Antistoflignende bindingsprotein ifølge krav 7, hvor det radioaktive mærke, imagografimidlet, det terapeutiske middel eller det diagnostiske middel er 110In, i:L1In, 177Lu, 18F, 52Fe, 62Cu, 64Cu, 67Cu, 67Ga, 68Ga, 86Y, 90Y, 89Zr, 94Tc, 94Tc, 99mTc, 120I, i23i, 124I, 125I, 131I, 154“158Gd, 32P, nC, 13N, 150, 186Re, 188Re, 51Mn, 52mMn, 55Co, 72As, 75Br, 76Br, 82mRb eller 83Sr.
9. Antistoflignende bindingsprotein ifølge krav 7 eller 8, hvor det radioaktive mærke, imagografimidlet, det terapeutiske middel eller det diagnostiske middel omfatter et eller flere midler til en imagografiplatform valgt fra gruppen, der består af MR-scanning (MRI); positronemissionstomografi (PET); enkeltfotonemissionstomografi (SPECT); optisk imagografi, computertomografi (CT); ultralyd, røntgen og fotoakustisk imagografi.
10. Isoleret nukleinsyremolekyle, der koder for polypeptiderne med formel [I] og [II] af det antistoflignende bindingsprotein ifølge et hvilket som helst af kravene 1 til 6.
11. Isoleret nukleinsyremolekyle ifølge krav 10, hvor nukleinsyremolekylet omfatter nukleotidsekvensen ifølge SEQ ID NO: 5 eller SEQ ID NO: 10.
12. Ekspressionsvektor, der omfatter nukleinsyremolekylet ifølge krav 10 eller 11.
13. Isoleret værtscelle, der omfatter nukleinsyremolekylet ifølge krav 10 eller 11 eller ekspressionsvektoren ifølge krav 12.
14. Fremgangsmåde til fremstilling af et antistoflignende bindingsprotein, der specifikt binder den tumorassocierede MUCl-syaloglycotop CA6, som omfatter ekspression i en celle af et eller flere nukleinsyremolekyler, der koder for polypeptider med strukturer som vist ved formlerne [I] og [II] nedenfor: Vli-Li-VL2-Cl [I] Vhi-L2-Vh2-Chi [II] hvor: Vli er et variabelt domæne af let kæde af immunoglobulin, der er afledt fra DS6-antistoffet; Vl2 er et variabelt domæne af let kæde af immunoglobulin, der er afledt fra DS6-antistoffet; Vhi er et variabelt domæne af tung kæde af immunoglobulin, der er afledt fra DS6-antistoffet; Vh2 er et variabelt domæne af tung kæde af immunoglobulin, der er afledt fra DS6-antistoffet; Cl er et konstant domæne af let kæde af immunoglobulin, såsom et humant IGKC konstant domæne af let kæde af immunoglobulin; Chi er et immunoglobulin Chi konstant domæne af tung kæde, såsom et humant immunoglobulin Chi konstant domæne af tung kæde; Li og L2 er aminosyrelinkere; hvor polypeptiderne med formel [I] og polypeptiderne med formel [II] danner et bivalent monospecifikt tandem-immunoglobulin-antistoflignende bindingsprotein; og hvor polypeptidet med formel [I] omfatter en sekvens, der er mindst 80 % identisk med SEQ ID NO: 1, og polypeptidet med formel [II] omfatter en sekvens, der er mindst 80 % identisk med SEQ ID NO: 7.
15. Fremgangsmåde ifølge krav 14, hvor Vli og Vl2 er defineret ved sekvensen SEQ ID NO: 2; og Vhi og Vh2 er defineret ved sekvensen SEQ ID NO: 8.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361761190P | 2013-02-05 | 2013-02-05 | |
| EP14305082 | 2014-01-21 | ||
| PCT/IB2014/000279 WO2014122529A1 (en) | 2013-02-05 | 2014-02-05 | Immuno imaging agent for use with antibody-drug conjugate therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2953977T3 true DK2953977T3 (da) | 2018-01-22 |
Family
ID=50031282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14717073.2T DK2953977T3 (da) | 2013-02-05 | 2014-02-05 | Immunimagografimiddel til anvendelse ved antistof-lægemiddel-konjugatterapi |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP2953977B1 (da) |
| JP (1) | JP6605331B2 (da) |
| KR (1) | KR20150113197A (da) |
| CN (1) | CN105229034B (da) |
| AU (1) | AU2014213687B2 (da) |
| CA (1) | CA2900154A1 (da) |
| DK (1) | DK2953977T3 (da) |
| ES (1) | ES2657053T3 (da) |
| HU (1) | HUE037909T2 (da) |
| LT (1) | LT2953977T (da) |
| MX (1) | MX2015010145A (da) |
| PL (1) | PL2953977T3 (da) |
| PT (1) | PT2953977T (da) |
| RU (1) | RU2015137858A (da) |
| SG (2) | SG11201506054XA (da) |
| SI (1) | SI2953977T1 (da) |
| WO (1) | WO2014122529A1 (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016202457A1 (en) * | 2015-06-15 | 2016-12-22 | Numab Ag | Hetero-dimeric multi-specific antibody format |
| CN110124057B (zh) * | 2019-06-06 | 2022-04-19 | 天津医科大学总医院 | 一种包含谷氨酰胺修饰的环糊精的抗肿瘤药物或药物载体 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2410551A1 (en) * | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
| JP2007503202A (ja) | 2003-07-21 | 2007-02-22 | イミュノジェン・インコーポレーテッド | Ｃａ６抗原特異的な細胞毒性コンジュゲートおよびその使用方法 |
| EP1917034A4 (en) * | 2005-08-22 | 2009-04-29 | Immunogen Inc | CA6 ANTIGEN-SPECIFIC CYTOTOXIC CONJUGATE AND METHOD OF ITS APPLICATION |
| GB0822001D0 (en) * | 2008-12-02 | 2009-01-07 | Glaxosmithkline Biolog Sa | Vaccine |
| BR112012004710A2 (pt) * | 2009-09-01 | 2016-08-16 | Abbott Lab | imunoglobulinas de domínio variável duplo e uso das mesmas |
| GB201005063D0 (en) * | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| UY32979A (es) * | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
-
2014
- 2014-02-05 KR KR1020157023998A patent/KR20150113197A/ko not_active Application Discontinuation
- 2014-02-05 SG SG11201506054XA patent/SG11201506054XA/en unknown
- 2014-02-05 ES ES14717073.2T patent/ES2657053T3/es active Active
- 2014-02-05 HU HUE14717073A patent/HUE037909T2/hu unknown
- 2014-02-05 CA CA2900154A patent/CA2900154A1/en not_active Abandoned
- 2014-02-05 CN CN201480018589.6A patent/CN105229034B/zh active Active
- 2014-02-05 EP EP14717073.2A patent/EP2953977B1/en active Active
- 2014-02-05 DK DK14717073.2T patent/DK2953977T3/da active
- 2014-02-05 SG SG10201707391QA patent/SG10201707391QA/en unknown
- 2014-02-05 PL PL14717073T patent/PL2953977T3/pl unknown
- 2014-02-05 MX MX2015010145A patent/MX2015010145A/es unknown
- 2014-02-05 WO PCT/IB2014/000279 patent/WO2014122529A1/en active Application Filing
- 2014-02-05 PT PT147170732T patent/PT2953977T/pt unknown
- 2014-02-05 SI SI201430556T patent/SI2953977T1/en unknown
- 2014-02-05 JP JP2015555820A patent/JP6605331B2/ja active Active
- 2014-02-05 RU RU2015137858A patent/RU2015137858A/ru not_active Application Discontinuation
- 2014-02-05 AU AU2014213687A patent/AU2014213687B2/en not_active Ceased
- 2014-02-05 LT LTEP14717073.2T patent/LT2953977T/lt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN105229034B (zh) | 2019-12-10 |
| SI2953977T1 (en) | 2018-02-28 |
| JP2016509606A (ja) | 2016-03-31 |
| ES2657053T3 (es) | 2018-03-01 |
| CN105229034A (zh) | 2016-01-06 |
| AU2014213687A1 (en) | 2015-08-20 |
| LT2953977T (lt) | 2018-02-12 |
| EP2953977A1 (en) | 2015-12-16 |
| SG10201707391QA (en) | 2017-10-30 |
| AU2014213687B2 (en) | 2018-12-06 |
| MX2015010145A (es) | 2016-05-31 |
| CA2900154A1 (en) | 2014-08-14 |
| RU2015137858A (ru) | 2017-03-13 |
| PL2953977T3 (pl) | 2018-04-30 |
| HUE037909T2 (hu) | 2018-09-28 |
| PT2953977T (pt) | 2018-01-29 |
| EP2953977B1 (en) | 2017-10-25 |
| WO2014122529A1 (en) | 2014-08-14 |
| JP6605331B2 (ja) | 2019-11-13 |
| KR20150113197A (ko) | 2015-10-07 |
| SG11201506054XA (en) | 2015-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7487250B2 (ja) | 標的分子に対する抗原結合コンストラクト | |
| Massa et al. | Site-specific labeling of cysteine-tagged camelid single-domain antibody-fragments for use in molecular imaging | |
| CN114716557A (zh) | Psma和cd3双特异性t细胞接合抗体构建体 | |
| KR20150131208A (ko) | Cd８에의 항원 결합 구조체들 | |
| US20180155449A1 (en) | Covalent disulfide-linked diabodies and uses thereof | |
| JP2017528449A (ja) | アミロイドーシスのための標的化免疫療法 | |
| Perols et al. | Influence of DOTA chelator position on biodistribution and targeting properties of 111In-labeled synthetic anti-HER2 affibody molecules | |
| JP6289733B2 (ja) | 癌の予防及び／又は治療に用いるための放射標識抗体断片 | |
| US9989524B2 (en) | Immuno imaging agent for use with antibody-drug conjugate therapy | |
| DK2953977T3 (da) | Immunimagografimiddel til anvendelse ved antistof-lægemiddel-konjugatterapi | |
| DK2953975T3 (da) | Immunbilleddannende middel til anvendelse ved antistof-lægemiddel-konjugatterapi | |
| US20220296737A1 (en) | Immunopet and immunospect imaging to identify cytotoxic t cell activity | |
| US9844607B2 (en) | Immuno imaging agent for use with antibody-drug conjugate therapy | |
| WO2022178642A1 (en) | Antibodies to igf2r and methods | |
| Delaney et al. | Site-specific photoaffinity bioconjugation for the creation of 89Zr-labeled radioimmunoconjugates | |
| US20030176663A1 (en) | Specific binding molecules for scintigraphy | |
| US20230190968A1 (en) | Anti-cd38 single-domain antibodies in disease monitoring and treatment | |
| WO2021229104A1 (en) | Anti-cd38 single-domain antibodies in disease monitoring and treatment | |
| WO2022242892A1 (en) | Anti-cd38 single-domain antibodies in disease monitoring and treatment | |
| CN116655793A (zh) | Bcma特异性诊疗一体化分子影像探针的制备方法及应用 | |
| JP2022501062A (ja) | Ｅｐｎ１を標的とする抗体 |